

Book Reviews

Editorial Policy. Recently published books and journals (one copy) are invited by the Editorial Office for announcement and review in ANTICANCER RESEARCH (no fee). Each announcement should include the full title of the publication, authors or editors, the number of pages, price, year of publication, ISBN and publisher. Publishers will be notified upon receipt of books and tear sheets of reviews will be sent after publication. Books will be returned to the sender only if the announcement is rejected. Reviews will be objective and clear regarding the content, quality and usefulness of the publication.

Tumor Models in Cancer Research. Second Edition.

Edited by B.A. Teicher.

2011, pp. 693, Eur 169.95, ISBN: 978-1-60761-967-3.
Springer Science + Business Media, New York, NY, USA.

The Editor and a panel of leading experts comprehensively describe the state-of-the-art in animal tumor model research. This volume updates and extends the comprehensive presentations in the first edition. The wide array of models detailed form the basis for the selection of compounds and treatments that go into clinical testing of patients, and include syngeneic models, human tumor xenograft models, orthotopic models, metastatic models, and genetically engineered mouse models. Synthesizing many years experience with all the major in vivo models currently available for the study of malignant disease, *Tumor Models in Cancer Research 2nd edition*, provides preclinical and clinical cancer researchers alike with a comprehensive guide to the selection of these models, their effective use, and the optimal interpretation of their results.

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care.

Edited by K.M. McMasters, J.-N. Vauthey.

2011, pp. 415, Eur 159.95, ISBN: 978-1-60327-521-7.
Springer Science + Business Media, New York, NY, USA.

This volume provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options. This volume also provides an up-to-date guide for treatment that explores not only traditional treatments, but newer investigational treatment options including surgical resection, liver transplantation, ablation (radiofrequency, microwave), percutaneous ethanol or acetic acid injection, transarterial chemoembolization (TACE), intra-arterial radiation therapy, and systemic chemotherapy. *Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care* will be of great value to all health care professionals and trainees worldwide who have an interest in the diagnosis and treatment of HCC, including surgeons, medical oncologists, radiologists, radiation oncologists, and pathologists.

Primary Central Nervous System Tumors. Pathogenesis and Therapy.

Edited by A.D. Norden, D. A. Reardon, P.Y.C. Wen.

2011, pp. 568, Eur 171.15, ISBN: 978-1-60761-165-3.
Springer Science + Business Media, New York, NY, USA.

This comprehensive, yet practical, text is a ready collection of the most up-to-date information on primary CNS tumors. Authored by a carefully selected group of the world's leading clinicians and scientists, the book is divided into three sections. The opening chapters cover general principles, including epidemiology, pathogenesis, tumor stem cells, supportive care, complications of therapy, and quality of life. The remaining two sections are comprised of treatment-oriented chapters covering the spectrum of gliomas and rarer tumor types. Each of these chapters presents multi-disciplinary therapeutic approaches and addresses specific disease concerns. Throughout, the authors incorporate the cutting-edge advances in molecular biology and genomics that are revolutionizing neuro-oncology. The result is an important clinical resource which provides evidence-based data and interpretation essential to intelligent therapeutic decision making.

Bladder Tumors: Molecular Aspects and Clinical Management.

Edited by V.B. Lokeshwar, A.S. Merseburger, S.H. Hautmann.

2011, pp. 466, Eur 160.45, ISBN: 978-1-60761-927-7.
Springer Science + Business Media, New York, NY, USA.

Clinical management of bladder cancer is challenging of the heterogeneity among bladder tumors with respect to invasion and metastasis, and frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments. Bladder cancer is also at the forefront of biomarker development because of the ease of developing noninvasive urine tests. The features of environment-driven carcinogenesis and divergent molecular pathways in the development of low- and high-grade tumors provide a unique opportunity for advance molecular research in cancer biology. *Bladder Tumors: Molecular Aspects and Clinical Management* is a collection of comprehensive reviews on the state-of-the art basic science research and clinical management of bladder cancer. The book progresses from epidemiology of bladder cancer, molecular basis of bladder carcinogenesis, to standard and molecular aspects of bladder cancer diagnosis and prognosis, and also includes various treatment aspects.

The contributing authors of this book are leaders in their respective areas of expertise-related to bladder cancer, and were assembled from different parts of the world. Since the editorial team of the book consists of a translational researcher (Vinata B. Lokeshwar) and urologists with expertise in clinical research (Stefan Hautmann and Axel S. Merseburger), it is the Editors' intent to promote an ongoing dialog among researchers and urologists to help reduce morbidity and mortality associated with bladder cancer, while improving the quality of life for patients.

Experimental and Applied Immunotherapy.

Edited by J. Medin, D. Fowler.

2011, pp. 442, Eur 160.45, ISBN: 978-1-60761-979-6.
Springer Science + Business Media, New York, NY, USA.

Immunotherapy is now recognized as an essential component of treatment for a wide variety of cancers. It is an interdisciplinary field that is critically dependent upon an improved understanding of a vast network of cross-regulatory cellular populations and a diversity of molecular effectors; it is a leading example of translational medicine with a favorable concept-to-clinical-trial timeframe of just a few years. There are many established immunotherapies already in existence, but there are exciting new cancer immunotherapies just on the horizon, which are likely to be more potent, less toxic and more cost effective than many therapies currently in use.

Experimental and Applied Immunotherapy is a state-of-the-art text offering a roadmap leading to the creation of these future cancer-fighting immunotherapies. It includes essays by leading researchers that cover a wide variety of topics including T cell and non-T cell therapy, monoclonal antibody therapy, dendritic cell-based cancer vaccines, Mesenchymal stromal cells, negative regulators in cancer immunology and immunotherapy, non-cellular aspects of cancer immunotherapy, the combining of cancer vaccines with conventional therapies, the combining of oncolytic viruses with cancer immunotherapy, transplantation, and more. The field of immunotherapy holds great promise that will soon come to fruition if creative investigators can bridge seemingly disparate disciplines, such as T cell therapy, gene therapy, and transplantation therapy. This text is a vital tool in the building of that bridge.

Oxford Textbook of Palliative Nursing.

Edited by B.R. Ferrell, N. Coyle.

2010, pp. 1381, £80.00, ISBN: 978-0-19-539134-3.
Oxford University Press, New York, NY, USA.

This is a comprehensive textbook dealing with all aspects of palliative nursing care, including current knowledge with explicit discussions and practical guidance with extensive literature.

Contents are divided into ten parts consisting of 78 chapters:

I. General principles; II. Symptom assessment and management; III. Psychological support; IV. Spiritual care; V. Special patient populations; VI. End-of-life care across settings; VII. Pediatric palliative care; VIII. Special issues for the Nurse in End-of-life care; IX. International models of palliative care; X. Conclusion.

This book is a leading resource in the field and will be particularly useful to nurses, oncologists and practitioners in all fields assisting their compassionate and important work.

Alcohol Consumption and Ethyl Carbamate. Volume 96, IARC.

Monographs on the Evaluation of Carcinogenic Risk to Humans.

2010, pp. 1424, US\$66.00, ISBN: 978-92-832-1296-6.
International Agency for Research on Cancer, Lyon, France.

This volume of the IARC Monographs contains evaluations of the carcinogenic hazard to humans of alcohol consumption and ethyl carbamate (urethane), a frequent contaminant of yeast-fermented foods and beverages.

The Working Group reviewed the epidemiological evidence on the possible association between alcoholic beverage consumption and cancer at 27 anatomical sites, and re-affirmed the previous conclusion (IARC, 1988) that cancers of the upper digestive tract (oral cavity, pharynx, larynx, oesophagus) and the liver are causally related to the consumption of alcoholic beverages. In addition the Working Group considered there is sufficient evidence to conclude that cancer of the colorectum and the female breast also belong in this list.

Regarding ethyl carbamate the Working Group concludes that there is inadequate evidence in humans for the carcinogenicity of ethyl carbamate. However, there is sufficient evidence in experimental animals for the carcinogenicity of ethyl carbamate, vinyl carbamate and vinyl carbamate epoxide.

For both alcohol and ethyl carbamate this volume presents comprehensively the current knowledge on: Exposure data, studies of cancer in humans, studies of cancer in experimental animals, and mechanistic and other relevant data.

Some Aromatic Amines, Organic Dyes, and Related Exposures.

Volume 99, IARC Monographs on the Evaluation of Carcinogenic Risk to Humans.

2010, pp. 692, US\$66.00, ISBN: 978-92-832-1299-7.
International Agency for Research on Cancer, Lyon, France.

This volume presents newer epidemiological and experimental data on the evaluation of the carcinogenic hazard to humans of some aromatic amines, organic dyes, and related occupational or consumer exposures. Information provided includes: Exposure data, studies of cancer in humans, studies of cancer in experimental animals, mechanistic and other relevant data and evaluation. The compounds examined and the conclusion for humans in parenthesis are as follows: 4-Aminobiphenyl (carcinogenic; causes bladder cancer); Auramine (auramine production causes bladder cancer); Benzidine (carcinogenic; causes bladder cancer); Dyes metabolized to benzidine (carcinogenic); Magenta (magenta production causes bladder cancer); 4,4'-Methylenebis (2-chloroaniline) (carcinogenic); 2-Naphthylamine (causes bladder cancer); ortho-Toluidine (causes bladder cancer); 4-Chloro-ortho-toluidine (probably carcinogenic); Hair colourants (occupational exposures as a hairdresser or barber are probably carcinogenic to humans; personal use of hair colourants is not classifiable as to its carcinogenicity to humans).

The IARC Monographs on the Evaluation of Carcinogenesis Risks to Humans are extremely important for human health and disease prevention and their conclusions should become readily and immediately available to the public.

Pharmacogenomic Testing in Current Clinical Practice. Implementation in the Clinical Laboratory.*Edited by A.H.B. Wu, K.-T.-J. Yeo.*

2011, pp. 272, Eur 171.15, ISBN: 978-1-60761-282-7. Springer Science + Business Media, New York, NY, USA.

While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. *Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory* focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, *Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory* is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.

Positron Emission Tomography.*Edited by M.E. Juweid, O.S. Hoekstra.*

2011, pp. 354, Eur 89.95, ISBN: 978-1-61779-061-4. Springer Science + Business Media, New York, NY, USA.

Oncological imaging has thoroughly changed in the past decade, especially due to the introduction of PET and 18FDG. In *Positron Emission Tomography*, expert referring specialists and professional imagers seek to help bridge some of the knowledge gaps in several oncological domains. The book's goal is to aid in the improvement of communicative competences: to communicate scan findings so that the referring specialist receives proper advice from the imager, and that, alternatively, the referring one provides the imager with appropriate clinical details to allow for a proper interpretation, and that the referring specialist is aware of the possibilities and limitations of the requested technology. While it focuses on FDG PET, other radiopharmaceuticals are covered as well, where appropriate. Written for the highly respected *Methods in Molecular Biology*TM series, this volume provides the kind of detailed description and implementation advice that is crucial for getting optimal results.

Authorative and convenient, this volume serves as an excellent reference for oncologists, surgeons, radiotherapists, radiologists, nuclear medicine physicians, and pathologists desiring a stronger synergy within their vital efforts.

Telomeres and Telomerases. Methods and Protocols. Second Edition.*Edited by Z. Songyang.*

2011, pp. 191, Eur 94.95, ISBN: 978-1-61779-091-1. Springer Science + Business Media, New York, NY, USA.

New and rapid advances in technology have equipped us with a variety of tools and platforms to ask fundamental questions of telomere regulation and have allowed investigators to carry out experiments using diverse model systems. For example, proteomic, genomic, and molecular approaches have afforded us unprecedented insight into the complex protein interaction networks at work on the telomere chromatin and the detailed information regarding telomere dynamics in response to stress or stimuli. *Telomeres and Telomerase: Methods and Protocols, Second Edition* builds upon the telomerase assays featured in the popular first edition to encompass many different assays that allow investigators to query the function of telomere proteins and the responses of the telomere DNA, including detailed examinations of biochemical, molecular, and proteomic approaches. Written in the highly successful *Methods in Molecular Biology*TM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and expert tips on troubleshooting and avoiding known pitfalls.

Authorative and practical, *Telomeres and Telomerase: Methods and Protocols, Second Edition* serves as an ideal, upto-date guide for investigators further pursuing this vital field of study.

Adult Acute Lymphocytic Leukemia. Biology and Treatment.*Edited by A.S. Advani, H.M. Lazarus.*

2011, pp. 388, Eur 159.95, ISBN: 978-1-60761-706-8. Springer Science + Business Media, New York, NY, USA.

The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors.

This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population.

Breast Cancer. A Lobar Disease.*Edited by T. Tot.*

2011, pp. 216, Eur 99.95, ISBN: 978-1-84996-313-8.

Springer-Verlag, London, UK.

The theory of the sick lobe states that breast carcinoma is a lobar disease developing most often within a single lobe, meaning that, at an early stage, breast carcinoma occupies a limited, anatomically well-defined portion of the breast. This theory unites observed patterns from the genetic, developmental and morphological perspectives, into an overall concept. *Breast Cancer: A Lobar Disease*, presents this hypothesis and its consequences. The body of evidence, pro and contra, generated in recent years is presented in this volume.

The chapters, all authored by leading experts in their respective areas, gather evidence from the perspectives of epidemiology, genetics, radiology, anatomy, developmental biology, morphology, endoscopy, ultrasound and therapeutics to give the reader a full picture of recent developments regarding the sick lobe hypothesis.

Skin Cancer – A World-Wide Perspective.*Edited by R. Dummer, M.R. Pittelkow, K. Iwatsuki, A. Green, N.M. Elwan.*

2011, pp. 398, Eur 159.95, ISBN: 978-3-642-05071-8.

Springer-Verlag, Berlin, Germany.

The dramatic increase in the incidence of skin cancers is a major concern worldwide and relates not only to melanoma but also to other cancers, including Merkel cell and basal cell carcinomas. Recently, the WHO has summarized the genetic and pathologic features of skin cancers in its book series. However, the WHO's proposed classification of certain disease entities, such as basal cell carcinomas, is still novel for many dermatologists. This book covers the entire spectrum of cutaneous malignancies in accordance with the new WHO classification. Epidemiology, pathogenesis, diagnosis, and therapy are all reviewed in detail, and care is taken to link the diagnostic and genetic features to optimized therapeutic strategies. In order to reflect the worldwide activities in the field, the editors have brought together leading researchers and clinicians from every continent to communicate their individual experiences and expertise. The result is a unique compilation of current medical and molecular knowledge about skin cancers. It is anticipated that this book will remain a basic reference for many years to come.

Pediatric Liver Tumors.*Edited by A. Zimmermann, G. Perilongo, M. Malogolowkin.*

2011, pp. 231, Eur 139.95, ISBN: 978-3-642-14503-2.

Springer-Verlag, Berlin, Germany.

The field of liver tumors in children, and in particular hepatoblastoma in infants and young children, has seen tremendous therapeutic advances over recent years. This has been achieved through a much better understanding of the

biology of disease, improved diagnostic procedures, refined methods of pretreatment tumor staging, the implementation of highly efficient chemotherapy and surgery, detailed monitoring of toxicity, and careful follow-up strategies. International controlled trials have played a key role in these advances, and many leading figures in the trials are among the editors and authors of this book. Their principal goal in *Hepatic Tumors in Children* is to provide the reader with a complete update on this complex and rapidly evolving field. All aspects of an impressive success story are covered, disclosing how the outcome of a previously devastating disease has been so dramatically improved. This book will prove essential reading for all who are involved in the care of children with liver tumors.

Blood and Marrow Transplantation Handbook. Comprehensive Guide for Patient Care.*Edited by R.T. Maziarz, S. Slater.*

2011, pp. 324, Eur 39.95, ISBN: 978-1-4419-7505-8.

Springer Science + Business Media, New York, NY, USA.

Developed by the Blood and Marrow Transplant team at Oregon Health & Science University Knight Cancer Institute, this pocket guide provides medical management guidelines for hematopoietic stem cell transplant patients from the moment of their initial consultation throughout the transplant process.

It includes indications for transplant, essential details for patient/donor evaluation; recommendations for addressing complications during and after transplant; long term follow up care; step-by-step instructions for common procedures and documentation guidelines.

An essential tool for providers, this guide presents a multidisciplinary approach to information vital for providing quality care for your patients.

Chemical Carcinogenesis.*Edited by T.M. Penning.*

2011, pp. 440, Eur 139.95, ISBN: 978-1-61737-994-9.

Springer Science + Business Media, New York, NY, USA.

This monograph provides a contemporary account of advances in chemical carcinogenesis. It promotes the view that it is alteration of the DNA by endogenous and exogenous carcinogens that ultimately leads to sporadic mutations which are a root cause of many human cancers. It deals with the metabolic activation of common classes of chemical carcinogens (tobacco carcinogens, heterocyclic amines, polycyclic aromatic hydrocarbons) and their detoxication. It describes the DNA-adducts that ensue and their repair mechanisms. It covers advances in structural-biology that provide a glimpse of both the DNA-repair process and the by-pass of DNA-lesions and how this informs the mutational code.

It also deals with the concepts of chemoprevention and biomarkers for biomonitoring human exposure. Many contemporary texts on the biology of cancer now focus almost exclusively on the molecular and cell biology of the disease and

do not cover the initiating (DNA damaging events) of chemical carcinogenesis in depth. It is with this perceived gap-in knowledge that world experts in their particular fields have contributed to this monograph. This monograph will be an important reference re-source for students in training, postdoctoral scientists, and senior scientists knowledgeable in the field.

Integrative Neuroscience and Personalized Medicine.

Edited by E. Gordon, S.H. Koslow.

2011, pp. 323, £55.00, ISBN: 978-0-19-539380-4.

Oxford University Press, New York, NY, USA.

This book takes an in-depth and hard look at the current status and future direction of treatment predictive markers in Personalized Medicine for the brain from the perspectives of the researchers on the cutting edge and those involved in healthcare implementation. The contents provide a comprehensive text suitable as both a pithy introduction to and a clear summary of the "science to solutions" continuum in this developing field of Personalized Medicine and Integrative Neuroscience. The science includes both measures of genes using whole genome approaches and SNIPS as well as BRAINmarkers of direct brain function such as brain imaging, biophysical changes and objective cognitive and behavioral measurements.

Personalized Medicine for Brain Disorders will soon be a reality using the comprehensive quantitative and standardized approaches to genomics, BRAINmarkers and cognitive function. Each chapter provides a review of recent relevant literature; show the solutions achieved through integrative neuroscience and applications in patient care thus providing a practical guide to the reader. The timeliness of this book's content is propitious providing bottom line information to educate practicing clinicians, health care workers and researchers, and also a pathway for undergraduate and graduates interested in further their understanding of and involvement in tailored personal solutions.

How Cancer Crossed the Color Line.

Edited by R. Wailoo.

2011, pp. 251, £17.99, ISBN: 978-0-19-517017-7.

Oxford University Press, New York, NY, USA.

In the course of the 20th century, cancer went from being perceived as a white woman's nemesis to a "democratic disease" to a fearsome threat in communities of color. Drawing on film and fiction, on medical and epidemiological evidence, and on patients' accounts, Keith Wailoo tracks this transformation in cancer awareness, revealing how not only awareness, but cancer prevention, treatment, and survival have all been refracted through the lens of race.

Spanning more than a century, the book offers a sweeping account of the forces that simultaneously defined cancer as an intensely individualized and personal experience linked to whites, often categorizing people across the color line as racial types lacking similar personal dimensions. Wailoo describes how theories of risk evolved with changes in women's roles, with African-American and new immigrant migration trends, with the growth of federal cancer surveillance, and with diagnostic advances, racial protest, and contemporary health activism. The book examines such powerful and transformative social developments as the mass black migration from rural south to urban north in the 1920s and 1930s, the World War II experience at home and on the war front, and the quest for civil rights and equality in health in the 1950s and '60s. It also explores recent controversies that illuminate the diversity of cancer challenges in America, such as the high cancer rates among privileged women in Marin County, California, the heavy toll of prostate cancer among black men, and the questions about why Vietnamese-American women's cervical cancer rates are so high.

Cancer Sourcebook. Sixth Edition.

Edited by K. Bellenir.

2011, pp. 1090, US\$95.00, ISBN: 978-0-7808-1145-4.

Ominographics, Detroit, MI, USA.

Every year, nearly 1.5 million Americans receive a diagnosis of cancer. Cancer is not a single disease, however. It is many different diseases that all share one common characteristic: Some of the body's cells do not die when they should. Instead they continue to grow and divide. Through this process, cancer cells can damage the body's tissues and organs, leading to a broad array of symptoms and even death. Although the survival rates for many types of cancer have improved in recent years and innovative treatment protocols are being developed, cancer remains the second leading cause of death in the United States.

Cancer Sourcebook, Sixth Edition provides updated information about common types of cancer affecting the central nervous system, endocrine system, lungs, digestive and urinary tracts, blood cells, immune system, skin, bones, and other body systems. It explains how people can reduce their risk of cancer by addressing issues related to cancer risk and taking advantage of screening exams. Various treatment choices—including surgery, chemotherapy, and radiation therapy—are discussed, and facts are provided about cancer clinical trials and other ongoing research. The book concludes with a glossary of related terms, a directory of national cancer organizations, and suggestions for finding community-based resources.